Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Anders

Showing results (181-190 of 247) with videos related to

Pageof 25
Sort By:
Scientific Reports|May 17, 2020
The Role of European Starlings (Sturnus vulgaris) in the Dissemination of Multidrug-Resistant Escherichia coli among Concentrated Animal Feeding OperationsJeffrey C Chandler, Jennifer E Anders, Nicolas A Blouin, et al.
Pediatric Blood & Cancer|October 21, 2011
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing programMalcolm A Smith, John M Maris, Richard Gorlick, et al.
Pediatric Blood & Cancer|January 23, 2016
Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing ProgramRichard Gorlick, E Anders Kolb, Stephen T Keir, et al.
Pediatric Blood & Cancer|September 22, 2016
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing programRichard Lock, Hernan Carol, John M Maris, et al.
Pediatric Blood & Cancer|September 30, 2014
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673Malcolm A Smith, Oliver A Hampton, C Patrick Reynolds, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2022
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphomaErica Brivio, André Baruchel, Auke Beishuizen, et al.
Blood|August 29, 2022
Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study reportLucie M Turcotte, Jillian A Whitton, Wendy M Leisenring, et al.
Cancer|December 22, 2017
Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trialL Lee Dupuis, Kara M Kelly, Jeffrey P Krischer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2019
Screening for Family Psychosocial Risk in Pediatric Hematopoietic Stem Cell Transplantation with the Psychosocial Assessment ToolAhna L H Pai, Avi Madan Swain, Fang Fang Chen, et al.
Pediatric Blood & Cancer|September 17, 2011
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing programMalcolm A Smith, Richard Gorlick, E Anders Kolb, et al.
Pageof 25

Showing results (181-190 of 247) with videos related to

Sort By:
Pageof 25
Scientific Reports|May 17, 2020
The Role of European Starlings (Sturnus vulgaris) in the Dissemination of Multidrug-Resistant Escherichia coli among Concentrated Animal Feeding OperationsJeffrey C Chandler, Jennifer E Anders, Nicolas A Blouin, et al.
Pediatric Blood & Cancer|October 21, 2011
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing programMalcolm A Smith, John M Maris, Richard Gorlick, et al.
Pediatric Blood & Cancer|January 23, 2016
Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing ProgramRichard Gorlick, E Anders Kolb, Stephen T Keir, et al.
Pediatric Blood & Cancer|September 22, 2016
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing programRichard Lock, Hernan Carol, John M Maris, et al.
Pediatric Blood & Cancer|September 30, 2014
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673Malcolm A Smith, Oliver A Hampton, C Patrick Reynolds, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2022
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphomaErica Brivio, André Baruchel, Auke Beishuizen, et al.
Blood|August 29, 2022
Chronic conditions, late mortality, and health status after childhood AML: a Childhood Cancer Survivor Study reportLucie M Turcotte, Jillian A Whitton, Wendy M Leisenring, et al.
Cancer|December 22, 2017
Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trialL Lee Dupuis, Kara M Kelly, Jeffrey P Krischer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 18, 2019
Screening for Family Psychosocial Risk in Pediatric Hematopoietic Stem Cell Transplantation with the Psychosocial Assessment ToolAhna L H Pai, Avi Madan Swain, Fang Fang Chen, et al.
Pediatric Blood & Cancer|September 17, 2011
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing programMalcolm A Smith, Richard Gorlick, E Anders Kolb, et al.
Pageof 25